{
    "id": "52831846",
    "text": "Ralimetinib (LY2228820) is a small molecule experiemental cancer drug in development by Eli Lilly. It is a p38 mitogen-activated protein kinase inhibitor. A phase II trial for treatment of ovarian cancer has completed. == References == Category:Experimental cancer drugs Category:Fluoroarenes Category:Imidazoles Category:Protein kinase inhibitors Category:Tert-butyl compounds Category:Clinical trials sponsored by Eli Lilly and Company ",
    "title": "Ralimetinib"
}